Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 8/2015

01-08-2015 | Review

Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome

Authors: Tsukasa Nozu, Toshikatsu Okumura

Published in: Journal of Gastroenterology | Issue 8/2015

Login to get access

Abstract

Irritable bowel syndrome (IBS) displays chronic abdominal pain or discomfort with altered defecation, and stress-induced altered gut motility and visceral sensation play an important role in the pathophysiology. Corticotropin-releasing factor (CRF) is a main mediator of stress responses and mediates these gastrointestinal functional changes. CRF in brain and periphery acts through two subtype receptors such as CRF receptor type 1 (CRF1) and type 2 (CRF2), and activating CRF1 exclusively stimulates colonic motor function and induces visceral hypersensitivity. Meanwhile, several recent studies have demonstrated that CRF2 has a counter regulatory action against CRF1, which may imply that CRF2 inhibits stress response induced by CRF1 in order to prevent it from going into an overdrive state. Colonic contractility and sensation may be explained by the state of the intensity of CRF1 signaling. CRF2 signaling may play a role in CRF1-triggered enhanced colonic functions through modulation of CRF1 activity. Blocking CRF2 further enhances CRF-induced stimulation of colonic contractility and activating CRF2 inhibits stress-induced visceral sensitization. Therefore, we proposed the hypothesis, i.e., balance theory of CRF1 and CRF2 signaling as follows. Both CRF receptors may be activated simultaneously and the signaling balance of CRF1 and CRF2 may determine the functional changes of gastrointestinal tract induced by stress. CRF signaling balance might be abnormally shifted toward CRF1, leading to enhanced colonic motility and visceral sensitization in IBS. This theory may lead to understanding the pathophysiology and provide the novel therapeutic options targeting altered signaling balance of CRF1 and CRF2 in IBS.
Literature
1.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–21, e1–4.
2.
Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–80.PubMed
3.
Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–5.PubMed
4.
Lau EM, Chan FK, Ziea ET, et al. Epidemiology of irritable bowel syndrome in Chinese. Dig Dis Sci. 2002;47:2621–4.PubMed
5.
Cryan JF, O’Mahony SM. The microbiome–gut–brain axis: from bowel to behavior. Neurogastroenterol Motil. 2011;23:187–92.PubMed
6.
Fukudo S, Nomura T, Muranaka M, et al. Brain–gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study. J Clin Gastroenterol. 1993;17:133–41.PubMed
7.
Heinrichs SC, Menzaghi F, Merlo Pich E, et al. The role of CRF in behavioral aspects of stress. Ann N Y Acad Sci. 1995;771:92–104.PubMed
8.
Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 1991;43:425–73.PubMed
9.
Turnbull AV, Rivier C. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med. 1997;215:1–10.PubMed
10.
Karalis K, Sano H, Redwine J, et al. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science. 1991;254:421–3.PubMed
11.
McInturf SM, Hennessy MB. Peripheral administration of a corticotropin-releasing factor antagonist increases the vocalizing and locomotor activity of isolated guinea pig pups. Physiol Behav. 1996;60:707–10.PubMed
12.
Schafer M, Mousa SA, Zhang Q, et al. Expression of corticotropin-releasing factor in inflamed tissue is required for intrinsic peripheral opioid analgesia. Proc Natl Acad Sci USA. 1996;93:6096–100.PubMedCentralPubMed
13.
Taché Y, Mönnikes H, Bonaz B, et al. Role of CRF in stress-related alterations of gastric and colonic motor function. Ann N Y Acad Sci. 1993;697:233–43.PubMed
14.
Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–31.PubMed
15.
Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol. 2014;20:2456–69.PubMedCentralPubMed
16.
Taché Y, Martínez V, Wang L, et al. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol. 2004;141:1321–30.PubMedCentralPubMed
17.
Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut. 1998;42:845–9.PubMedCentralPubMed
18.
Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004;53:958–64.PubMedCentralPubMed
19.
Nozu T, Kudaira M. Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans. J Gastroenterol. 2006;41:740–4.PubMed
20.
Vale W, Spiess J, Rivier C, et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394–7.PubMed
21.
Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287–92.PubMed
22.
Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA. 2001;98:2843–8.PubMedCentralPubMed
23.
Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA. 2001;98:7570–5.PubMedCentralPubMed
24.
Hauger RL, Grigoriadis DE, Dallman MF, et al. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev. 2003;55:21–6.PubMed
25.
Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev. 2006;27:260–86.PubMed
26.
Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci. 1999;885:312–28.PubMed
27.
Blank T, Nijholt I, Grammatopoulos DK, et al. Corticotropin-releasing factor receptors couple to multiple G-proteins to activate diverse intracellular signaling pathways in mouse hippocampus: role in neuronal excitability and associative learning. J Neurosci. 2003;23:700–7.PubMed
28.
29.
30.
Bonaz B, Taché Y. Water-avoidance stress-induced c-fos expression in the rat brain and stimulation of fecal output: role of corticotropin-releasing factor. Brain Res. 1994;641:21–8.PubMed
31.
Lenz HJ, Raedler A, Greten H, et al. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. Gastroenterology. 1988;95:1510–7.PubMed
32.
Fargeas MJ, Fioramonti J, Bueno L. Central action of interleukin 1 beta on intestinal motility in rats: mediation by two mechanisms. Gastroenterology. 1993;104:377–83.PubMed
33.
Mönnikes H, Schmidt BG, Raybould HE, et al. CRF in the paraventricular nucleus mediates gastric and colonic motor response to restraint stress. Am J Physiol Gastrointest Liver Physiol. 1992;262:G137–43.
34.
Mönnikes H, Schmidt BG, Taché Y. Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology. 1993;104:716–23.PubMed
35.
Martínez V, Rivier J, Wang L, et al. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J Pharmacol Exp Ther. 1997;280:754–60.PubMed
36.
Nakade Y, Fukuda H, Iwa M, et al. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physiol Gastrointest Liver Physiol. 2007;292:G1037–44.PubMed
37.
Lenz HJ, Burlage M, Raedler A, et al. Central nervous system effects of corticotropin-releasing factor on gastrointestinal transit in the rat. Gastroenterology. 1988;94:598–602.PubMed
38.
Miyata K, Ito H, Fukudo S. Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. Am J Physiol Gastrointest Liver Physiol. 1998;274:G827–31.
39.
Martínez V, Wang L, Million M, et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides. 2004;25:1733–44.PubMed
40.
Martínez V, Wang L, Rivier J, et al. Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J Physiol. 2004;556:221–34.PubMedCentralPubMed
41.
Ataka K, Kuge T, Fujino K, et al. Wood creosote prevents CRF-induced motility via 5-HT3 receptors in proximal and 5-HT4 receptors in distal colon in rats. Auton Neurosci. 2007;133:136–45.PubMed
42.
Mönnikes H, Schmidt BG, Tebbe J, et al. Microinfusion of corticotropin releasing factor into the locus coeruleus/subcoeruleus nuclei stimulates colonic motor function in rats. Brain Res. 1994;644:101–8.PubMed
43.
Raadsheer FC, Hoogendijk WJ, Stam FC, et al. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 1994;60:436–44.PubMed
44.
Weiss JM, Stout JC, Aaron MF, et al. Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res Bull. 1994;35:561–72.PubMed
45.
Arborelius L, Skelton KH, Thrivikraman KV, et al. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154, 526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther. 2000;294:588–97.PubMed
46.
Luiten PG, ter Horst GJ, Karst H, et al. The course of paraventricular hypothalamic efferents to autonomic structures in medulla and spinal cord. Brain Res. 1985;329:374–8.PubMed
47.
Silverman AJ, Hou-Yu A, Chen WP. Corticotropin-releasing factor synapses within the paraventricular nucleus of the hypothalamus. Neuroendocrinology. 1989;49:291–9.PubMed
48.
Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev. 2003;42:33–84.PubMed
49.
Butler PD, Weiss JM, Stout JC, et al. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci. 1990;10:176–83.PubMed
50.
Koob GF. Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry. 1999;46:1167–80.PubMed
51.
Garakani A, Win T, Virk S, et al. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther. 2003;10:61–7.PubMed
52.
American Gastroenterology Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology. 2002;123:2105–7.
53.
Million M, Wang L, Martínez V, et al. Differential Fos expression in the paraventricular nucleus of the hypothalamus, sacral parasympathetic nucleus and colonic motor response to water avoidance stress in Fischer and Lewis rats. Brain Res. 2000;877:345–53.PubMed
54.
Castagliuolo I, Lamont JT, Qiu B, et al. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol Gastrointest Liver Physiol. 1996;271:G884–92.
55.
Williams CL, Peterson JM, Villar RG, et al. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol Gastrointest Liver Physiol. 1987;253:G582–6.
56.
Maillot C, Million M, Wei JY, et al. Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology. 2000;119:1569–79.PubMed
57.
Kimura T, Amano T, Uehara H, et al. Urocortin I is present in the enteric nervous system and exerts an excitatory effect via cholinergic and serotonergic pathways in the rat colon. Am J Physiol Gastrointest Liver Physiol. 2007;293:G903–10.PubMed
58.
Nozu T, Takakusaki K, Okumura T. A balance theory of peripheral corticotropin-releasing factor receptor type 1 and type 2 signaling to induce colonic contractions and visceral hyperalgesia in rats. Endocrinology. 2014;155:4655–64.PubMed
59.
Martínez V, Wang L, Rivier JE, et al. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther. 2002;301:611–7.PubMed
60.
Million M, Maillot C, Saunders P, et al. Human urocortin II, a new CRF-related peptide, displays selective CRF2-mediated action on gastric transit in rats. Am J Physiol Gastrointest Liver Physiol. 2002;282:G34–40.PubMed
61.
Larauche M, Gourcerol G, Wang L, et al. Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol. 2009;297:G215–27.PubMedCentralPubMed
62.
Gourcerol G, Wu SV, Yuan PQ, et al. Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents. Gastroenterology. 2011;140:1586–96, e1–6.
63.
Yuan PQ, Wu SV, Wang L, et al. Corticotropin releasing factor in the rat colon: expression, localization and upregulation by endotoxin. Peptides. 2010;31:322–31.PubMedCentralPubMed
64.
Chatzaki E, Crowe PD, Wang L, et al. CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. J Neurochem. 2004;90:309–16.PubMed
65.
von Mentzer B, Murata Y, Ahlstedt I, et al. Functional CRF receptors in BON cells stimulate serotonin release. Biochem Pharmacol. 2007;73:805–13.
66.
Theoharides TC, Donelan JM, Papadopoulou N, et al. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci. 2004;25:563–8.PubMed
67.
Wallon C, Yang PC, Keita AV, et al. Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. Gut. 2008;57:50–8.PubMed
68.
Audhya T, Jain R, Hollander CS. Receptor-mediated immunomodulation by corticotropin-releasing factor. Cell Immunol. 1991;134:77–84.PubMed
69.
Kawahito Y, Sano H, Kawata M, et al. Local secretion of corticotropin-releasing hormone by enterochromaffin cells in human colon. Gastroenterology. 1994;106:859–65.PubMed
70.
Muramatsu Y, Fukushima K, Iino K, et al. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides. 2000;21:1799–809.PubMed
71.
Wu SV, Yuan PQ, Lai J, et al. Activation of Type 1 CRH receptor isoforms induces serotonin release from human carcinoid BON-1N cells: an enterochromaffin cell model. Endocrinology. 2011;152:126–37.PubMedCentralPubMed
72.
Overman EL, Rivier JE, Moeser AJ. CRF induces intestinal epithelial barrier injury via the release of mast cell proteases and TNF-alpha. PLoS One. 2012;7:e39935.PubMedCentralPubMed
73.
Kempuraj D, Papadopoulou NG, Lytinas M, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology. 2004;145:43–8.PubMed
74.
Fukumoto S, Tatewaki M, Yamada T, et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1269–76.PubMed
75.
Yuan PQ, Million M, Wu SV, et al. Peripheral corticotropin releasing factor (CRF) and a novel CRF1 receptor agonist, stressin1-A activate CRF1 receptor expressing cholinergic and nitrergic myenteric neurons selectively in the colon of conscious rats. Neurogastroenterol Motil. 2007;19:923–36.PubMed
76.
Bisschops R, Vanden Berghe P, Sarnelli G, et al. CRF-induced calcium signaling in guinea pig small intestine myenteric neurons involves CRF-1 receptors and activation of voltage-sensitive calcium channels. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1252–60.PubMed
77.
Tsukamoto K, Nakade Y, Mantyh C, et al. Peripherally administered CRF stimulates colonic motility via central CRF receptors and vagal pathways in conscious rats. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1537–41.PubMed
78.
Perrin MH, Donaldson CJ, Chen R, et al. Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology. 1993;133:3058–61.PubMed
79.
Wang L, Martínez V, Vale W, et al. Fos induction in selective hypothalamic neuroendocrine and medullary nuclei by intravenous injection of urocortin and corticotropin-releasing factor in rats. Brain Res. 2000;855:47–57.PubMed
80.
Maillot C, Wang L, Million M, et al. Intraperitoneal corticotropin-releasing factor and urocortin induce Fos expression in brain and spinal autonomic nuclei and long lasting stimulation of colonic motility in rats. Brain Res. 2003;974:70–81.PubMed
81.
Menetrey D, De Pommery J. Origins of spinal ascending pathways that reach central areas involved in visceroception and visceronociception in the rat. Eur J Neurosci. 1991;3:249–59.PubMed
82.
Hay M, Bishop VS. Interactions of area postrema and solitary tract in the nucleus tractus solitarius. Am J Physiol Heart Circ Physiol. 1991;260:H1466–73.
83.
Van Pett K, Viau V, Bittencourt JC, et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol. 2000;428:191–212.PubMed
84.
Mercer JG, Lawrence CB, Copeland PA. Corticotropin-releasing factor binding sites undergo axonal transport in the rat vagus nerve. J Neuroendocrinol. 1992;4:281–6.PubMed
85.
Davis SF, Derbenev AV, Williams KW, et al. Excitatory and inhibitory local circuit input to the rat dorsal motor nucleus of the vagus originating from the nucleus tractus solitarius. Brain Res. 2004;1017:208–17.PubMedCentralPubMed
86.
Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109:40–52.PubMed
87.
Mayer EA, Raybould HE. Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology. 1990;99:1688–704.PubMed
88.
van der Veek PP, Van Rood YR, Masclee AA. Symptom severity but not psychopathology predicts visceral hypersensitivity in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2008;6:321–8.PubMed
89.
Kuiken SD, Lindeboom R, Tytgat GN, et al. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:157–64.PubMed
90.
Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology. 1994;107:271–93.PubMed
91.
Posserud I, Syrous A, Lindstrom L, et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology. 2007;133:1113–23.PubMed
92.
Prior A, Sorial E, Sun W-M, et al. Irritable bowel syndrome: differences between patients who show rectal sensitivity and those who do not. Eur J Gastroenterol Hepatol. 1993;5:343–9.
93.
Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122:1771–7.PubMed
94.
Nozu T, Kudaira M, Kitamori S, et al. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol. 2006;41:217–22.PubMed
95.
Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology. 1997;112:55–63.PubMed
96.
Gué M, Del Rio-Lacheze C, Eutamene H, et al. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil. 1997;9:271–9.PubMed
97.
Schwetz I, McRoberts JA, Coutinho SV, et al. Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats. Am J Physiol Gastrointest Liver Physiol. 2005;289:G704–12.PubMed
98.
Greenwood-Van Meerveld B, Johnson AC, Cochrane S, et al. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterol Motil. 2005;17:415–22.PubMed
99.
Kosoyan HP, Grigoriadis DE, Taché Y. The CRF(1) receptor antagonist, NBI-35965, abolished the activation of locus coeruleus neurons induced by colorectal distension and intracisternal CRF in rats. Brain Res. 2005;1056:85–96.PubMed
100.
Su J, Tanaka Y, Muratsubaki T, et al. Injection of corticotropin-releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats. Neurogastroenterol Motil. 2015;27:30–9.PubMed
101.
Kim SH, Han JE, Hwang S, et al. The expression of corticotropin-releasing factor in the central nucleus of the amygdala, induced by colorectal distension, is attenuated by general anesthesia. J Korean Med Sci. 2010;25:1646–51.PubMedCentralPubMed
102.
Neugebauer V, Li W, Bird GC, et al. The amygdala and persistent pain. Neuroscientist. 2004;10:221–34.PubMed
103.
Phelps EA, LeDoux JE. Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron. 2005;48:175–87.PubMed
104.
De Francesco PN, Valdivia S, Cabral A, et al. Neuroanatomical and functional characterization of CRF neurons of the amygdala using a novel transgenic mouse model. Neuroscience. 2015;289C:153–65.
105.
Gray TS, Bingaman EW. The amygdala: corticotropin-releasing factor, steroids, and stress. Crit Rev Neurobiol. 1996;10:155–68.PubMed
106.
Kravets JL, Reyes BA, Unterwald EM, et al. Direct targeting of peptidergic amygdalar neurons by noradrenergic afferents: linking stress-integrative circuitry. Brain Struct Funct. 2015;220:541–58.PubMed
107.
108.
Coutinho SV, Plotsky PM, Sablad M, et al. Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol. 2002;282:G307–16.PubMed
109.
Nemeroff CB. Neurobiological consequences of childhood trauma. J Clin Psychiatry. 2004;65(Suppl 1):18–28.PubMed
110.
Ladd CO, Thrivikraman KV, Huot RL, et al. Differential neuroendocrine responses to chronic variable stress in adult Long Evans rats exposed to handling-maternal separation as neonates. Psychoneuroendocrinology. 2005;30:520–33.PubMed
111.
Francis DD, Caldji C, Champagne F, et al. The role of corticotropin-releasing factor—norepinephrine systems in mediating the effects of early experience on the development of behavioral and endocrine responses to stress. Biol Psychiatry. 1999;46:1153–66.PubMed
112.
Kalinichev M, Easterling KW, Plotsky PM, et al. Long-lasting changes in stress-induced corticosterone response and anxiety-like behaviors as a consequence of neonatal maternal separation in Long-Evans rats. Pharmacol Biochem Behav. 2002;73:131–40.PubMed
113.
Larauche M, Bradesi S, Million M, et al. Corticotropin-releasing factor type 1 receptors mediate the visceral hyperalgesia induced by repeated psychological stress in rats. Am J Physiol Gastrointest Liver Physiol. 2008;294:G1033–40.PubMed
114.
Million M, Wang L, Wang Y, et al. CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut. 2006;55:172–81.PubMedCentralPubMed
115.
Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23:1067–76.PubMed
116.
van den Wijngaard RM, Klooker TK, de Jonge WJ, et al. Peripheral relays in stress-induced activation of visceral afferents in the gut. Auton Neurosci. 2010;153:99–105.PubMed
117.
Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology. 2007;132:26–37.PubMed
118.
Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol. 2011;106:1290–8.PubMed
119.
Ait-Belgnaoui A, Bradesi S, Fioramonti J, et al. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain. 2005;113:141–7.PubMed
120.
Nakade Y, Tsuchida D, Fukuda H, et al. Restraint stress augments postprandial gastric contractions but impairs antropyloric coordination in conscious rats. Am J Physiol Regul Integr Comp Physiol. 2006;290:R616–24.PubMed
121.
Million M, Maillot C, Adelson DA, et al. Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats. Peptides. 2005;26:1188–95.PubMed
122.
Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol. 2009;5:374–81.PubMed
123.
Nozu T, Tsuchiya Y, Kumei S, et al. Peripheral corticotropin-releasing factor (CRF) induces stimulation of gastric contractions in freely moving conscious rats: role of CRF receptor types 1 and 2. Neurogastroenterol Motil. 2013;25:190–7.PubMed
124.
O’malley D, Julio-Pieper M, Gibney SM, et al. Differential stress-induced alterations of colonic corticotropin-releasing factor receptors in the Wistar Kyoto rat. Neurogastroenterol Motil. 2010;22:301–11.PubMed
125.
Liu S, Ren W, Qu MH, et al. Differential actions of urocortins on neurons of the myenteric division of the enteric nervous system in guinea pig distal colon. Br J Pharmacol. 2010;159:222–36.PubMedCentralPubMed
126.
Posserud I, Agerforz P, Ekman R, et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut. 2004;53:1102–8.PubMedCentralPubMed
127.
Fukudo S, Kanazawa M, Kano M, et al. Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol. 2002;37(Suppl 14):145–50.PubMed
128.
Fukudo S, Suzuki J. Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome. Tohoku J Exp Med. 1987;151:373–85.PubMed
129.
Tanaka Y, Kanazawa M, Fukudo S, et al. Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17:131–9.PubMedCentralPubMed
130.
Rittenhouse PA, Lopez-Rubalcava C, Stanwood GD, et al. Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat. Psychoneuroendocrinology. 2002;27:303–18.PubMed
131.
Gunter WD, Shepard JD, Foreman RD, et al. Evidence for visceral hypersensitivity in high-anxiety rats. Physiol Behav. 2000;69:379–82.PubMed
132.
Courvoisier H, Moisan MP, Sarrieau A, et al. Behavioral and neuroendocrine reactivity to stress in the WKHA/WKY inbred rat strains: a multifactorial and genetic analysis. Brain Res. 1996;743:77–85.PubMed
133.
Sato N, Suzuki N, Sasaki A, et al. Corticotropin-releasing hormone receptor 1 gene variants in irritable bowel syndrome. PLoS One. 2012;7:e42450.PubMedCentralPubMed
134.
Hsu DT, Mickey BJ, Langenecker SA, et al. Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing. J Neurosci. 2012;32:3253–60.PubMedCentralPubMed
135.
Markovic D, Grammatopoulos DK. Focus on the splicing of secretin GPCRs transmembrane-domain 7. Trends Biochem Sci. 2009;34:443–52.PubMed
136.
Sweetser S, Camilleri M, Linker Nord SJ, et al. Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome? Am J Physiol Gastrointest Liver Physiol. 2009;296:G1299–306.PubMedCentralPubMed
137.
Suda T, Kageyama K, Sakihara S, et al. Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides. 2004;25:1689–701.PubMed
138.
Nozu T, Martínez V, Rivier J, et al. Peripheral urocortin delays gastric emptying: role of CRF receptor 2. Am J Physiol Gastrointest Liver Physiol. 1999;276:G867–74.
139.
Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2012;46(Suppl):S52–5.PubMed
140.
Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33.PubMed
141.
Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–83.PubMed
142.
Labus JS, Dinov ID, Jiang Z, et al. Irritable bowel syndrome in female patients is associated with alterations in structural brain networks. Pain. 2014;155:137–49.PubMedCentralPubMed
143.
Larauche M, Kiank C, Taché Y. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol. 2009;60(Suppl 7):33–46.PubMedCentralPubMed
144.
Mayer EA, Savidge T, Shulman RJ. Brain–gut microbiome interactions and functional bowel disorders. Gastroenterology. 2014;146:1500–12.PubMedCentralPubMed
145.
Labus JS, Hubbard CS, Bueller J, et al. Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome. Gastroenterology. 2013;145:1253–61, e1–3.
Metadata
Title
Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome
Authors
Tsukasa Nozu
Toshikatsu Okumura
Publication date
01-08-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 8/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1086-8

Other articles of this Issue 8/2015

Journal of Gastroenterology 8/2015 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C

Original Article—Alimentary Tract

Time series analysis of gastric acid secretion over a 20-year period in normal Japanese men

Original Article—Alimentary Tract

Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial

Original Article—Alimentary Tract

No increase in gastric acid secretion in healthy Japanese over the past two decades

Review

Recognition of and recent issues in hereditary diffuse gastric cancer

Original Article—Liver, Pancreas, and Biliary Tract

Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits